The mechanisms that drive disease have long confounded the medical industry. How much of a part does genetics play? How does the patient’s lifestyle influence his or her risk of developing cancer? What makes one patient respond favorably to a particular treatment, while another suffers severe side effects?
Browsing: NEWS
1) Findings: Insights and developments globally on the subject.
2) Companies: Updates and progress reports on member companies.
3) Industry: Important developments from throughout the field.
The Cleveland Clinic has unveiled its latest Top 10 Medical Innovations list, highlighting technologies that are expected to have a big impact in 2009. Announced during Cleveland Clinic’s 2008 Medical Innovation Summit,, the list was determined by a panel of Cleveland Clinic physicians and scientists. 10. Private Sector National Health Information Exchange: A comprehensive system of electronic health records that link consumers, general practitioners, specialists, hospitals, pharmacies, nursing homes, and insurance companies is in the process of being established. Primarily a private-sector effort, this computerized system has the potential to replace paper-based medical files with digitized records of patients’ complete…
Irvington-NY based Electro-Optical Sciences (EOS), developer of The MelaFind System, a handheld imaging device that detects melanomas at an early stage, announced last week that its pivotal trial sites have closed: all follow-up data has been received and is now undergoing third-party statistical validation. The company will announce top-line results in the next few weeks. For many investors, the news has been a long time coming. Shares of the company, which had been trading near a 52-week low, have increased by 50 percent. In a previous blinded trial examining 352 suspicious pigmented skin lesions, MelaFind had 100% sensitivity in finding…
The OneMedPlace finance conference for emerging med tech companies, the OneMedForum, will be held January 13-14 in San Francisco. Click here to learn more. Our featured panelists and speakers will be recognized experts that can offer insights and a unique perspective on their respective area of expertise. Each panel will be focus on disrupters and drivers; companies will exhibit after each discussion. Orthopedics and Spine: During the last 10 years venture investment in orthopedic start-ups has been on the rise. Venture investors have primarily been focused on the spine and to a lesser extent on sports medicine, joint reconstruction and…
Magnetic resonance imaging (MRI) of the breast continues to show double digit growth in 2008 and is one of the fastest growing procedures in radiology departments, this according to Arlington Medical Resources (AMR), a diagnostic imaging research firm. In the first half of 2008, the total number of patients undergoing MRI of the breast increased 23 percent over the same period last year. MRI of the breast is typically used to diagnose breast cancer. Beginning in 2007, the American Cancer Society began recommending breast MRI as a screening modality for the 1.4 million American women at high risk for the…
Our in-house dynamo, Claudia Pinzon and the rest of the the talented team at OneMedTV, have been busy compiling a wealth of valuable video content captured at AdvaMed2008. Below, some of that footage. To watch the videos, click the thumbnail or visit OneMedPlace.tv. Veralight: David VanAvermaete from Veralight presents a new approach to non-invasive diabetes screening through earlier detection and complication reduction. Microtransponder: T. Jordan Curnes from Microtransponder talks about a wireless neurostimulation device for chronic pain management. BioControl: BioControl speaks about their latest innovations in the pathogen detection space. Chemica Technologies: Chemica Technologies is a research-oriented, biotechnology-focused company. Mesynthes:…
Critical Care Innovations (CCI), a biotechnology-driven device company, is developing minimally-invasive, site-specific and image-guided cancer management systems. By using ultrasound guidance and visualization technologies, along with its proprietary cryothermal and microencapsulation processes, the company has created a unique, site-specific and controlled release cancer management diagnostic and therapeutic system. The company’s microencapsulated controlled delivery process can deliver, with accuracy, individualized therapeutic and concentrated doses of chemotherapeutics directly into targeted regions of the patient’s cancerous tissue, providing sustained release of drugs. By encapsulating drugs, CCI has improved the effectiveness of chemotherapy, lowering toxicity and virtually eliminating side effects.
BSD Medical, a developer of microwave systems used to treat cancer, has received FDA 510(k) clearance for its MicroThermX-100 Microwave Ablation System (MTX-100). MTX-100 is indicated for use in the ablation of soft tissue. The device provides minimally invasive access to the target tissue and can be used in open surgical as well as in percutaneous ablation procedures. The delivery of microwave energy is controlled using a touch-screen monitor. MTX-100 will compete head-on with RF ablation technologies that require patient grounding pads. The device can be used both by surgeons and interventional radiologists. According to the company, MTX-100 will be…